TheTechno Optimist.

Oral WegovyNovo Nordisk—FDA approves oral Wegovy (semaglutide 25 mg) as first oral GLP-1 for obesityWegovy (semaglutide)Novo Nordisk—Semaglutide's patent expires in India and many generic versions launchNovo Nordisk—Novo Nordisk's US decision on haemophilia drug denecimig slips past third quarter 2026Wegovy (semaglutide)Novo Nordisk—FDA approves Wegovy pill, oral semaglutide 25 mg, for weight managementOral WegovyNovo Nordisk—Oral Wegovy surpasses 3 million prescriptions in five months following January 2026 launchEfruxiferminNovo Nordisk—Novo Nordisk completes its acquisition of Akero; efruxifermin joins its MASH pipeline

Efruxifermin

by Novo NordiskDK

Become the first drug shown to reverse cirrhosis caused by fatty-liver disease (MASH), a stage where no approved medicine has proven benefit, and pair with Novo's GLP-1 drugs.

PilotStage 3 of 5

Three Phase 3 trials running; safety results due Q4 2026, first biopsy results (F2-F3 MASH) in H1 2027.

Updated 9 Dec 2025Checked 11 Oct0 updates this week

Milestones

Next · SYNCHRONY Real-World safety results (F1-F4)
  1. SYMMETRY Phase 2b: cirrhosis reversal at week 9627 Jan 2025Complete.
  2. Novo agrees to buy Akero for up to $5.2B9 Oct 2025Complete.
  3. Akero acquisition closes9 Dec 2025Complete.
  4. SYNCHRONY Real-World safety results (F1-F4)Target Q4 2026Current milestone.
  5. SYNCHRONY Histology 52-week biopsy results (F2-F3)Target 2027Not yet reached.
  6. SYNCHRONY Outcomes primary completion (cirrhosis)Target Feb 2030Not yet reached.

Most important updates

Upcoming

  1. Q4 2026SYNCHRONY Real-World safety results (F1-F4) (next)
  2. 2027SYNCHRONY Histology 52-week biopsy results (F2-F3)
  3. Feb 2030SYNCHRONY Outcomes primary completion (cirrhosis)
Primer